NasdaqGS:AMLXPharmaceuticals
Is Amylyx Pharmaceuticals' (AMLX) New GLP-1 Rare Disease Bet Expanding or Diluting Its Core Strategy?
Earlier in January 2026, Amylyx Pharmaceuticals announced it had selected AMX0318, a long-acting GLP-1 receptor antagonist discovered with Gubra A/S, as a development candidate for post-bariatric hypoglycemia and other rare diseases following extensive preclinical evaluation.
The move expands Amylyx’s pipeline into GLP-1 biology and rare metabolic conditions, while triggering up to US$50 million in potential milestones and mid-single digit royalties to Gubra, including US$4 million tied to...